B. Braun announces investment in British wearable sensor technology company 270 Vision

B. Braun Melsungen AG has announced a strategic investment in 270 Vision Limited, a UK-based developer of wearable sensor technology. B. Braun is one of the world’s leading manufacturers of medical devices and pharmaceutical products and services, with 58,000 employees in 64 countries and a turnover of 6.13 billion Euro in 2015. Product design and development company 270 Vision focuses on innovative wearable medical-grade sensors and advanced body data analysis technology for professional sports and medical sectors. The acquisition suits the therapy field of Orthopaedic Joint Replacement represented at the B. Braun Division Aesculap AG.

“The protagonists of the arthroplasty market – medical professionals, health care providers and patients – are confronted with a range of new financial, outcome based and efficiency challenges”, describes Darren Lee, Vice President Orthopaedics and Spine, B. Braun Medical Ltd, the market background. “The demands of an aging population and limited financial resources invite us to accelerate the transition to a patient pathway model of care. We improve all phases around surgery and therefore consider 270 Vision with BPMpathway as an excellent and vital part of our unique concepts for patients and medical experts.”

The TOTAL pathway concept analyses, assesses and reshapes clinical processes and delivers tailored solutions for the critical phases prior to, during and after the surgery. It intends to accelerate and enhance patient recovery, and simultaneously reduce costs and enhance efficiency for the care providers. From the initial patient consultation to rehabilitation it provides progress in patient safety, process workflow, patient satisfaction and health economic advantages.

BPMPathway, one of 270 Vision’s main products, generates added value to the process of rehabilitation. It enables doctors to discharge orthopaedic patients early and monitor them at home. Shortening the duration of the patient’s time in the hospital, this technology and concept reduce costs for the National Health Service.

Patients have been highly interested in the intuitive technology - fascinated by a clear visualisation of their progress. Driven by increased motivation they invested more energy and efforts in their therapy. BPMPathway also identifies potential complications during the recovery in an early phase, so that those might be taken care of quickly. This potentially reduces the risk of further hospitalisation and surgery. “This is the first orthopaedic analysis tool to deliver a simultaneous, accurate, cost-effective assessment of the range and quality of joint movement during rehabilitation. Developing those in the context of TOTAL Pathway offers tremendous advantages for patients and their attending doctors,” explains Martin Gossling, CEO and co-founder of 270 Vision.

“In health care, the overarching goal for solution providers, as well as for every other stakeholder, must be improving value for patients by achieving health targets in a cost efficient way. By introducing TOTAL Pathway, Aesculap innovated each patient touch point, from the first contacts of people in pain up to the moment when they are active, reintegrated members of the community again. We identified BPMPathway from 270 Vision as the ideal partner for this endeavour,” said Dr. Jens von Lackum, Member of the Executive Board Aesculap AG.

-ENDS-